Peramivir
Brand names: Rapivab · Active ingredient: Peramivir
In short: RAPIVAB is indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 2 days. Limitations of Use: Efficacy of RAPIVAB is based on clinical trials of naturally occurring influenza in which the predominant influenza infections
What is Peramivir used for?
RAPIVAB is indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 2 days.
Limitations of Use:
Efficacy of RAPIVAB is based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza A virus; a limited number of subjects infected with influenza B virus were enrolled.
Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RAPIVAB .
The efficacy of RAPIVAB could not be established in patients with serious influenza requiring hospitalization .
Peramivir dosage
Administer RAPIVAB within 2 days of onset of symptoms of influenza.
Adults and Adolescents (13 years of age and older)
The recommended dosage of RAPIVAB in adult and adolescent patients 13 years of age and older with acute uncomplicated influenza is a single 600 mg dose, administered via intravenous infusion for 15 to 30 minutes.
Pediatric Patients (6 months to 12 years of age)
The recommended dosage of RAPIVAB in pediatric patients 6 months to 12 years of age with acute uncomplicated influenza is a single 12 mg/kg dose (up to a maximum dose of 600 mg), administered via intravenous infusion for 15 to 30 minutes.
Significantly increased drug exposures were observed when RAPIVAB was administered to adult subjects with renal dysfunction . Therefore, the RAPIVAB dosage should be reduced for patients with baseline creatinine clearance below 50 mL/min using the recommendations in Table 1 and Table 2. No dosage adjustment is required for single administration of RAPIVAB in patients with creatinine clearance of 50 mL/min or higher .
In patients with chronic renal impairment maintained on hemodialysis, RAPIVAB should be administered after dialysis at a dose adjusted based on renal function (Table 1 and Table 2) .
Creatinine Clearancea (mL/min)
≥50 | 30 to 49 | 10 to 29
a Calculated using the Cockcroft and Gault equation.
Recommended Dose (mg) | 600 mg | 200 mg | 100 mg
Creatinine Clearancea (mL/min)
≥50 | 30 to 49 | 10 to 29
a
Calculated using the Cockcroft and Gault equation.
b Up to maximum dose of 600 mg.
Recommended Dose (mg/kg)b | 12 mg/kg | 4 mg/kg | 2 mg/kg
No data are available to inform a recommendation for dosage adjustment with RAPIVAB in pediatric patients 6 months to less than 2 years of age with creatinine clearance less than 50 mL/min .
Use aseptic technique during the preparation of RAPIVAB to prevent inadvertent microbial contamination. There is no preservative or bacteriostatic agent present in the solution.
Follow the steps below to prepare a diluted solution of RAPIVAB:
(a)Do not use if seal over bottle opening is broken or missing.
(b)Visually inspect RAPIVAB for particulate matter and discoloration prior to administration.
(c) Dilute an appropriate dose of RAPIVAB 10 mg/mL solution in 0.9% or 0.45% sodium chloride, 5% dextrose, or lactated Ringer's. The maximum infusion volume is provided in Table 3. The final concentration of diluted RAPIVAB for administration should be between 1 mg/mL and 6 mg/mL.
Table 3. Maximum Infusion Volume by Age and Weight
Age
Weight (kg)
Maximum Infusion Volumea (mL)
a
Infusion volume is the total volume of RAPIVAB 10 mg/mL solution and diluent. The final concentration of diluted RAPIVAB for administration should be between 1 mg/mL and 6 mg/mL. …
How to take Peramivir — instructions & advice from the label
Advise patients of the following:
There is a risk of severe allergic reactions (including anaphylaxis) or serious skin reactions with RAPIVAB use. Advise patients to seek immediate medical attention if an allergic-like reaction occurs or is suspected .
There is a risk of neuropsychiatric events in patients with influenza. Patients should contact their physician if they experience signs of abnormal behavior after receiving RAPIVAB .
Warnings & precautions
Do not take this medicine if: RAPIVAB is contraindicated in patients with known serious hypersensitivity or anaphylaxis to peramivir or any component of the product. Severe allergic reactions have included anaphylaxis, erythema multiforme, and Stevens-Johnson syndrome .
Rare cases of serious skin reactions, including erythema multiforme, have been reported with RAPIVAB in clinical studies and in postmarketing experience. Cases of anaphylaxis and Stevens-Johnson syndrome have been reported in postmarketing experience with RAPIVAB. Discontinue RAPIVAB and institute appropriate treatment if anaphylaxis or a serious skin reaction occurs or is suspected. The use of RAPIVAB is contraindicated in patients with known serious hypersensitivity or anaphylaxis to RAPIVAB .
Influenza can be associated with a variety of neurologic and behavioral symptoms that can include events such as hallucinations, delirium, and abnormal behavior, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur in uncomplicated influenza as well.
There have been postmarketing reports of delirium and abnormal behavior leading to injury in patients with influenza who were receiving neuraminidase inhibitors, including RAPIVAB. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made, but they appear to be uncommon. These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution. The contribution of RAPIVAB to these events has not been established. Patients with influenza should be closely monitored for signs of abnormal behavior.
There is no evidence for efficacy of RAPIVAB in any illness caused by agents other than influenza viruses. …
Peramivir side effects
The following adverse reactions are discussed in other sections of the labeling:
Serious skin and hypersensitivity reactions
Neuropsychiatric events
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions in Adults (18 years of age and older)
In 5 randomized, double-blind, controlled trials, 1,399 subjects with acute uncomplicated influenza received a single dose of RAPIVAB, administered intravenously or intramuscularly, at doses up to 600 mg. Among the 664 subjects receiving RAPIVAB 600 mg (intravenous or intramuscular), the most commonly observed adverse reaction was diarrhea, occurring at a rate of 8% versus 7% in subjects receiving placebo. No subject receiving RAPIVAB 600 mg experienced a serious adverse event and <1% discontinued study because of an adverse reaction.
Clinically significant laboratory abnormalities (DAIDS Grades 2 to 4) listed in Table 4 occurred more frequently in subjects treated with RAPIVAB 600 mg (intravenous or intramuscular) than placebo. Only events occurring at ≥2% are included.
Laboratory Parameter Abnormalitya | RAPIVAB 600 mg | Placebo
a Frequencies based on treatment-emergent laboratory abnormalities. …
Drug interactions
This section describes clinically relevant drug interactions with RAPIVAB. Drug-drug interaction studies are described elsewhere in the labeling .
Inactivated influenza vaccine can be administered at any time relative to use of RAPIVAB. For live attenuated influenza vaccine (LAIV), antiviral drugs may inhibit viral replication and thus may reduce vaccine efficacy. The concurrent use of RAPIVAB with LAIV intranasal has not been evaluated. Because of the potential for interference between these two products, avoid use of LAIV within 2 weeks before or 48 hours after administration of RAPIVAB unless medically indicated.
About this medicine
RAPIVAB (peramivir) is an inhibitor of influenza virus neuraminidase. The chemical name is (1S,2S,3R,4R)-3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-(carbamimidoylamino)-2-hydroxycyclopentanecarboxylic acid, trihydrate. The chemical formula is C15H28N4O4 ∙ 3H2O, representing a molecular weight of 382.45. The molecular structure is as follows:
RAPIVAB injection is a clear, colorless, sterile, isotonic solution (200 mg per 20 mL) in glass vials fitted with rubber stoppers and royal blue flip-off seals. Each mL contains 10 mg peramivir (on an anhydrous basis) in 0.9% sodium chloride solution. The pH may have been adjusted with sodium hydroxide, USP and/or hydrochloric acid, USP. The pH is 5.5 to 8.5.
How it works: Peramivir is an antiviral drug with activity against influenza virus . At twice the maximum recommended dose, RAPIVAB did not prolong the QTc interval to any clinically relevant extent. The pharmacokinetics of RAPIVAB was evaluated in Phase 1 trials in adults.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID fe04f6cd-e71c-4bd4-abac-97720bba2a0d. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin